Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Pinter

Showing results (121-130 of 127) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 127 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
Dermatology and Therapy|December 19, 2023
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)A Pinter, A Costanzo, S Khattri, et al.
Annals of Tropical Medicine and Parasitology|January 29, 2009
Ecological aspects of the free-living ticks (Acari: Ixodidae) on animal trails within Atlantic rainforest in south-eastern BrazilM P J Szabó, M B Labruna, M V Garcia, et al.
The British Journal of Dermatology|April 22, 2020
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)A S Paller, M M B Seyger, G Alejandro Magariños, et al.
AIDS Research and Human Retroviruses|July 20, 1996
In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160S H Pincus, K Wehrly, R Cole, et al.
The British Journal of Dermatology|September 4, 2020
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trialA Blauvelt, C Leonardi, B Elewski, et al.
The British Journal of Dermatology|June 22, 2017
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severityC C Zouboulis, T Tzellos, A Kyrgidis, et al.
Pageof 13

Showing results (121-130 of 127) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 127 results.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
Dermatology and Therapy|December 19, 2023
Comparative Effectiveness and Durability of Biologics in Clinical Practice: Month 12 Outcomes from the International, Observational Psoriasis Study of Health Outcomes (PSoHO)A Pinter, A Costanzo, S Khattri, et al.
Annals of Tropical Medicine and Parasitology|January 29, 2009
Ecological aspects of the free-living ticks (Acari: Ixodidae) on animal trails within Atlantic rainforest in south-eastern BrazilM P J Szabó, M B Labruna, M V Garcia, et al.
The British Journal of Dermatology|April 22, 2020
Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)A S Paller, M M B Seyger, G Alejandro Magariños, et al.
AIDS Research and Human Retroviruses|July 20, 1996
In vitro effects of anti-HIV immunotoxins directed against multiple epitopes on HIV type 1 envelope glycoprotein 160S H Pincus, K Wehrly, R Cole, et al.
The British Journal of Dermatology|September 4, 2020
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trialA Blauvelt, C Leonardi, B Elewski, et al.
The British Journal of Dermatology|June 22, 2017
Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severityC C Zouboulis, T Tzellos, A Kyrgidis, et al.
Pageof 13